← Cytek Biosciences, Inc.
| Annual Trend | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Net Income (Loss) Available to Common Stockholders, Basic | $3.2m |
$0
-100.00%
|
$2.6m |
($12.1m)
-571.58%
|
($6.0m)
+50.44%
|
($66.5m)
-1005.30%
|
— | |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | $19.4m | $3.0m | $2.5m | ($12.1m) | ($6.0m) | ($66.5m) | — | |
| Net Income (Loss) Attributable to Noncontrolling Interest | — | $26k | $92k | $0 | $0 | $0 | — | |
| Depreciation, Depletion and Amortization | $603k | $1.2m | $2.5m | $6.0m | $7.2m | $7.6m | $11.9m | |
| Amortization of Intangible Assets | $71k | $334k | $835k | $3.3m | $3.7m | $3.7m | — | |
| Depreciation | $532k | $908k | $1.7m | $2.8m | $3.5m | $3.9m | $11.9m | |
| Deferred Income Tax Expense (Benefit) | ($7.4m) | ($1.8m) | ($11.3m) | ($10.0m) | ($2.9m) | $33.6m | $35.8m | |
| Share-based Payment Arrangement, Noncash Expense | $611k | $6.6m | $16.6m | $22.0m | $26.8m | $24.6m | $21.4m | |
| Share-based Payment Arrangement, Expense | $611k | $6.6m | $16.6m | $22.0m | $26.8m | $24.6m | $21.4m | |
| Nonoperating Income (Expense) | $771k | ($3.2m) | $3.1m | $12.1m | $14.8m | $10.5m | — | |
| Other Nonoperating Income (Expense) | $994k | ($1.5m) | $1.0m | $7.8m | $4.5m | $8.8m | — | |
| Changes in operating assets and liabilities: | ||||||||
| Increase (Decrease) in Accounts Receivable | $334k | $12.4m | $19.7m | $7.3m | $5.4m | ($368k) | $4.9m | |
| Increase (Decrease) in Inventories | $5.7m | $7.1m | $17.7m | ($4.3m) | ($14.8m) | $5.2m | ($4.7m) | |
| Inventory Write-down | $1.6m | $488k | $756k | $1.5m | $1.6m | $1.7m | — | |
| Increase (Decrease) in Accounts Payable | ($55k) | ($256k) | $1.9m | ($1.8m) | $2.6m | $448k | $1.4m | |
| Net Cash Provided by (Used in) Operating Activities | $15.2m |
$4.6m
-69.45%
|
($12.2m)
-364.17%
|
$5.3m
+143.18%
|
$25.4m
+380.57%
|
($4.7m)
-118.46%
|
($6.0m)
-28.87%
|
|
| Cash flows from investing activities: | ||||||||
| Payments to Acquire Property, Plant, and Equipment | $1.5m | $4.4m | $9.7m | $4.6m | $3.5m | $4.1m | ($6.1m) | |
| Gain (Loss) on Disposition of Property Plant Equipment | — | $0 | $0 | ($7k) | ($55k) | ($415k) | ($4.8m) | |
| Marketable Securities, Unrealized Gain (Loss) | — | — | $17k | ($29k) | $97k | $58k | — | |
| Net Cash Provided by (Used in) Investing Activities | ($1.5m) | ($21.0m) | ($55.9m) | ($93.9m) | ($83.0m) | $10.1m | ($3.0m) | |
| Cash flows from financing activities: | ||||||||
| Payments for Repurchase of Common Stock | — | — | — | $44.2m | $21.6m | $15.1m | — | |
| Net Cash Provided by (Used in) Financing Activities | $122.6m |
$213.6m
+74.18%
|
$5.5m
-97.42%
|
($41.8m)
-858.43%
|
($15.8m)
+62.16%
|
($13.4m)
+15.11%
|
$3.9m
+128.89%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $135.6m | $198.5m | ($65.1m) | ($131.9m) | ($68.9m) | ($7.9m) | $70.3m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $166.1m | $364.6m | $299.5m | $167.6m | $98.7m | $90.9m | $70.3m | |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | ($587k) | $1.3m | ($2.5m) | ($1.4m) | $4.5m | $109k | $3.5m | |
| Additional Supplementary Disclosures | ||||||||
| Additional Supplementary Disclosures | ||||||||
| Supplemental disclosure of cash flow information: | ||||||||
| Income Taxes Paid, Net | $2.1m | $2.9m | $10.4m | $5.3m | $3.8m | $2.2m | — | |
| Additional Financial Items | ||||||||
| Equity Securities, FV-NI, Gain (Loss) | $0 | $40k | $0 | $0 | — | — | — | |
| Gain (Loss) Related to Litigation Settlement | — | — | — | — | — | ($1.0m) | — | |
| General and Administrative Expense | $9.4m | $20.8m | $34.7m | $44.0m | $43.1m | $58.9m | — | |
| Goodwill | $476k | $10.1m | $10.1m | $16.2m | $16.7m | $16.7m | — | |
| Income Tax Expense (Benefit) | ($5.0m) | $2.9m | ($1.2m) | ($3.6m) | $320k | $36.7m | — | |
| Interest Expense Nonoperating | — | — | — | — | ($5.2m) | $474k | — | |
| Investment Income, Interest | $110k | $49k | $4.6m | $6.4m | $5.1m | $2.2m | — | |
| Operating Expenses | $38.1m | $70.0m | $102.8m | $137.3m | $131.6m | $144.8m | — | |
| Proceeds from Stock Options Exercised | $169k | $642k | $1.2m | $1.5m | $1.0m | $325k | — |